Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. (Q44370069)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 March 2013

Language	Label	Description	Also known as
English	Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.	scientific article published on 15 March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

object named as

Ignace Vergote

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

author name string

Florian Heitz

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Andreas du Bois

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Philipp Harter

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Dirk Lubbe

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Christian Kurzeder

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Marie Plante

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Jacobus Pfisterer

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

AGO study group

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

NCIC-CTG study group

10

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

EORTC-GCG study group

11

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

0 references

publication date

15 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

129

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

463-466

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Stress hormone-mediated invasion of ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Surgical stress promotes tumor growth in ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Beta Blockers and Breast Cancer Mortality: A Population- Based Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Impact of beta blockers on epithelial ovarian cancer survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.007

7 January 2021

Identifiers

10.1016/J.YGYNO.2013.03.007

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44370069&oldid=1401865077"